CN110412285B - 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用 - Google Patents

抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用 Download PDF

Info

Publication number
CN110412285B
CN110412285B CN201910489605.4A CN201910489605A CN110412285B CN 110412285 B CN110412285 B CN 110412285B CN 201910489605 A CN201910489605 A CN 201910489605A CN 110412285 B CN110412285 B CN 110412285B
Authority
CN
China
Prior art keywords
cells
mcm
desacetylmangiferin
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910489605.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110412285A (zh
Inventor
梁纯
姜志宏
王紫壹
禹志领
王静蓉
白丽萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong Kong University of Science and Technology
Hong Kong Baptist University
Macau University of Science and Technology
Original Assignee
Hong Kong University of Science and Technology
Hong Kong Baptist University
Macau University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Kong University of Science and Technology, Hong Kong Baptist University, Macau University of Science and Technology filed Critical Hong Kong University of Science and Technology
Publication of CN110412285A publication Critical patent/CN110412285A/zh
Application granted granted Critical
Publication of CN110412285B publication Critical patent/CN110412285B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
CN201910489605.4A 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用 Active CN110412285B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261644442P 2012-05-09 2012-05-09
US61/644,442 2012-05-09
PCT/US2013/040287 WO2013169989A1 (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment
CN201380024370.2A CN104736157B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380024370.2A Division CN104736157B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用

Publications (2)

Publication Number Publication Date
CN110412285A CN110412285A (zh) 2019-11-05
CN110412285B true CN110412285B (zh) 2022-11-15

Family

ID=49551267

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910489605.4A Active CN110412285B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用
CN201380024370.2A Active CN104736157B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380024370.2A Active CN104736157B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用

Country Status (9)

Country Link
US (1) US11648258B2 (enExample)
EP (2) EP2846807B1 (enExample)
JP (6) JP2015517500A (enExample)
CN (2) CN110412285B (enExample)
AU (1) AU2013259486B2 (enExample)
CA (2) CA2873283C (enExample)
ES (1) ES2949335T3 (enExample)
IN (1) IN2014MN02513A (enExample)
WO (1) WO2013169989A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019283946B2 (en) * 2017-05-19 2021-05-20 Enkang Pharmaceuticals (Guangzhou), Ltd. Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms
CN117756875A (zh) 2017-05-19 2024-03-26 恩康药业科技（广州）有限公司 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用
CN114129582A (zh) * 2019-03-27 2022-03-04 天津中医药大学 黄夹次乙苷作为抗肿瘤药物的应用
WO2025077888A1 (zh) 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 一种适合外用的化合物及药物组合物
EP4792817A1 (en) 2023-10-13 2026-08-19 EnKang Pharmaceuticals (Guangzhou), Ltd. Compound and method for treating and/or preventing skin cancer or precancerous lesion thereof
WO2025077886A1 (zh) 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法
JP2025107691A (ja) 2024-01-09 2025-07-22 シャープ株式会社 端末装置、方法、および集積回路

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014343A1 (en) * 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
WO2005099747A1 (en) * 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
CN101683359A (zh) * 2008-09-28 2010-03-31 上海秀新臣邦医药科技有限公司 一种治疗肿瘤的中药组合物及其制备方法
CN101726577A (zh) * 2008-10-13 2010-06-09 中山大学 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592990A (ja) 1991-08-06 1993-04-16 Taisho Pharmaceut Co Ltd カルデノライド誘導体
US7393950B2 (en) 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
US8318922B2 (en) 2002-08-29 2012-11-27 The Hong Kong Polytechnic University Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
DE10248751A1 (de) 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
NZ556158A (en) 2004-12-22 2010-04-30 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same
EP1787645A1 (en) 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
US20090018088A1 (en) * 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides
WO2010068247A1 (en) 2008-12-10 2010-06-17 Sloan-Kettering Institute For Cancer Research Cardenolides for the treatment of ocular cancer
CN102219821A (zh) 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014343A1 (en) * 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
WO2005099747A1 (en) * 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
CN101683359A (zh) * 2008-09-28 2010-03-31 上海秀新臣邦医药科技有限公司 一种治疗肿瘤的中药组合物及其制备方法
CN101726577A (zh) * 2008-10-13 2010-06-09 中山大学 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer;Gouji Toyokawa等;《Molecular Cancer》;20111231;第10卷(第1期);第1-11页 *
New Cytotoxic Cardenolide Glycoside from the Seeds of Cerbera manghas;Sarot Cheenpracha等;《Chem. Pharm. Bull.》;20040831;第52卷(第8期);第1023-1025页 *
海杧果属红树植物的化学成分及其生物活性研究概述;徐艳等;《广西科学院学报》;20110228;第27卷(第1期);第55-61页 *

Also Published As

Publication number Publication date
CN104736157B (zh) 2019-06-11
EP2846807A1 (en) 2015-03-18
AU2013259486B2 (en) 2019-12-12
US11648258B2 (en) 2023-05-16
CA2873283A1 (en) 2013-11-14
US20150099712A1 (en) 2015-04-09
JP2015517500A (ja) 2015-06-22
WO2013169989A1 (en) 2013-11-14
JP2021193132A (ja) 2021-12-23
EP2846807A4 (en) 2016-07-27
CA3111702A1 (en) 2013-11-14
CN104736157A (zh) 2015-06-24
EP4248978A2 (en) 2023-09-27
JP2025169320A (ja) 2025-11-12
CA2873283C (en) 2021-05-04
JP2024001049A (ja) 2024-01-09
CA3111702C (en) 2025-03-18
EP4248978A3 (en) 2023-11-08
JP2018100274A (ja) 2018-06-28
AU2013259486A1 (en) 2014-12-18
JP2020073544A (ja) 2020-05-14
IN2014MN02513A (enExample) 2015-07-17
ES2949335T3 (es) 2023-09-27
EP2846807B1 (en) 2023-06-07
CN110412285A (zh) 2019-11-05
EP2846807C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
JP2025169320A (ja) Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
Zhao et al. Potent effects of dioscin against gastric cancer in vitro and in vivo
Winnicka et al. Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells
Tao et al. Corn silk crude polysaccharide exerts anti-pancreatic cancer activity by blocking the EGFR/PI3K/AKT/CREB signaling pathway
Gao et al. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma
Qin et al. Yulangsan polysaccharide inhibits 4T1 breast cancer cell proliferation and induces apoptosis in vitro and in vivo
Tan et al. Gypensapogenin H suppresses tumor growth and cell migration in triple-negative breast cancer by regulating PI3K/AKT/NF-κB/MMP-9 signaling pathway
Li et al. The effect of dihydroartemisinin on the malignancy and epithelial-mesenchymal transition of gastric cancer cells
Dai et al. Discovery of potent immune-modulating molecule taccaoside A against cancers from structures-active relationships of natural steroidal saponins
Liu et al. Hesperidin derivative-11 inhibits fibroblast-like synoviocytes proliferation by activating Secreted frizzled-related protein 2 in adjuvant arthritis rats
Li et al. KLF4 suppresses anticancer effects of brusatol via transcriptional upregulating NCK2 expression in melanoma
Tu et al. Icaritin ameliorates extracellular microparticles‐induced inflammatory pre‐metastatic niche via modulating the cGAS‐STING signaling
Zhu et al. Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells
US20160298119A1 (en) Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising hrp-3 inhibitor
Liu et al. LingZhi oligopeptides amino acid sequence analysis and anticancer potency evaluation
Meng et al. Inhibition of the interaction between Hippo/YAP and Akt signaling with ursolic acid and 3′ 3-diindolylmethane suppresses esophageal cancer tumorigenesis
Huang et al. Phragmunis a suppresses glioblastoma through the regulation of MCL1-FBXW7 by blocking ELK1-SRF complex-dependent transcription
Fallit et al. Targeting FOXP3 in glioblastoma: Blockade of tumor intrinsic effects boosts response to chemo-radiotherapy
US20230293564A1 (en) Method and compounds for inhibiting the MCM complex and their application in cancer treatment
Wang et al. Role of mimic of manganese superoxide dismutase in proliferation and apoptosis of gastric carcinoma BGC-823 cells in vitro and in vivo
HK40016841B (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
HK40016841A (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
HK40100635A (en) Method and compounds for inhibiting the mcm complex and their application in cancer treatment
Guo et al. Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells
Ye et al. Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016841

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant